text
"['\nXII. 상세표\n1. 연결대상 종속회사 현황(상세)\n☞ 본문 위치로 이동\n(단위 : 천원)\n상호\n설립일\n주소\n주요사업\n최근사업연도말자산총액\n지배관계 근거\n주요종속회사 여부\n(주)힐리언스\n2005.07\n대한민국\n생활습관병예방연구\n30,789,082\xa0\n지배기업의종속기업\n-\nDAEWOONG PHARMACEUTICAL HONGKONG\n2013.07\n홍콩\n지주회사\n45,459,179\xa0\n지배기업의종속기업\n-\n요녕대웅제약유한공사\n2008.07\n중국\n의약품 제조 및 판매\n33,965,478\xa0\nDAEWOONG PHARMACEUTICAL HONGKONG의 종속기업\n-\nPT. Daewoong Pharmaceutical(Indonesia)Co.,Ltd.\n2005.12\n인도네시아\n의약품 판매\n11,896,827\xa0\n지배기업의종속기업\n-\nPT. DAEWOONG INFION\n2013.02\n인도네시아\n의약품 제조 및 판매\n11,268,275\xa0\nPT. Daewoong Pharmaceutical(Indonesia)Co.,Ltd.의 종속기업\n-\nDaewoong Pharma PHILIPPINES INC.\n2007.05\n필리핀\n의약품 판매\n3,623,988\xa0\n지배기업의종속기업\n-\nDaewoong Pharmaceutical(Thailand)Co.,Ltd.\n2007.07\n태국\n의약품 판매\n1,235,160\xa0\n지배기업의종속기업\n-\n한올바이오파마㈜\n1973.11.\n대한민국\n의약품 판매\n196,561,208\xa0\n지배기업의종속기업\n○(지배회사 자산총액의 10% 이상)\nHPI,INC.\n2007.08\n미국\nFDA임상시험 진행\n278,996\xa0\n한올바이오파마(주)의 종속기업\n-\n북경대웅위업의약과기유한공사\n2007.07\n중국\n의약품 연구\n3,242,301\xa0\n지배기업의종속기업\n-\nDaewoong Pharmaceutical India Pvt.,Ltd.\n2012.11\n인도\n의약품 연구\n960,934\xa0\n지배기업의종속기업\n-\nDaewoong America, Inc.\n2009.12\n미국\n의약품 연구\n53,606\xa0\n지배기업의종속기업\n-\nDaewoong Pharmaceutical(Japan)Co., Ltd.\n2017.03\n일본\n의약품 제조 및 판매\n1,747,491\xa0\n지배기업의종속기업\n-\n아피셀테라퓨틱스\n2020.01\n대한민국\n의약품 연구\n13,718,205\xa0\n지배기업의종속기업\n-\n아이엔테라퓨틱스\n2020.05\n대한민국\n의약품 연구\n9,715,180\xa0\n지배기업의종속기업\n-\nDaewoong innovation holdings\n2021.05\n미국\n의약품 연구\n2,366,987\xa0\n지배기업의종속기업\n-\nDaewoong Biologics Indonesia\n2021.09\n인도네시아\n의약품 제조 및 판매\n3,163,142\xa0\nPT. Daewoong Pharmaceutical(Indonesia)Co.,Ltd.의 종속기업\n-\n* 상기 최근사업연도말 자산총액은\xa02021년말\xa0기준입니다.\n2. 계열회사 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2021년 12월 31일\n)\n(단위 : 사)\n상장여부\n회사수\n기업명\n법인등록번호\n상장\n3\n(주)대웅\n131111-0000271\n(주)대웅제약\n134811-0075342\n한올바이오파마(주)\n164111-0000397\n비상장\n33\n대웅바이오(주)\n134811-0172221\n(주)대웅생명과학\n210111-0013294\n(주)대웅경영개발원\n110111-0776463\n(주)산웅개발\n110111-0978671\n(주)대웅이엔지\n134811-0034421\n(주)팜팩\n134811-0048307\n(주)대웅개발\n131111-0083649\n(주)아이디에스앤트러스트\n110111-1234006\n㈜에이치알그룹\n110111-2041872\n㈜에스티에이치이솔루션\n110111-4326735\n(주)대웅테라퓨틱스\n135811-0360271\n(주)힐리언스\n110111-3265778\n다나아데이터㈜\n110111-6935790\n(주)엠디웰아이엔씨\n110111-3716854\n농업회사법인(주)대웅낙원\n141411-0009986\n(주)아피셀테라퓨틱스\n134511-0431912\n(주)아이엔테라퓨틱스\n134511-0459592\n(주)대웅펫\n110111-7040457\nDaewoong Pharma PHILIPPINES INC.\n-\n북경대웅위업의약과기유한공사\n-\nDaewoong Pharmaceutical(Thailand)Co.,Ltd\n-\nDaewoong America, Inc.\n-\nPT. Daewoong Pharmaceutical(Indonesia)Co.Ltd\n-\n사천대웅생물기술유한공사\n-\nDAEWOONG PHARMACEUTICAL HONGKONG\n-\nDaewoong Pharmaceutical India Pvt.,Ltd\n-\nDaewoong Pharmaceutical Japan Co., Ltd.\n-\nHPI,INC\n-\n요녕대웅제약유한공사\n-\nPT. DAEWOONG INFION\n-\nDaewoong Bio Indonesia\n-\nDaewoong Innovation Holdings\n-\nDaewoong Biologics Indonesia\n-\n* 지주회사 : (주)대웅* 자회사 : (주)대웅제약 외 12개사* 손자회사 : (주)한올바이오파마 외 6개사* 해외법인 : Daewoong Pharma PHILIPPINES INC. 외 14개사\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2021년 12월 31일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n한올바이오파마(주)\n상장\n-\n경영참여\n116,111,366\n16,115,745\n31\n116,111,366\n-\n-\n-\n16,115,745\n31\n116,111,366\n196,561,209\n8,960,481\n힐리언스\n비상장\n-\n경영참여\n27,310,924\n2,753,300\n76\n14,434,620\n100,000\n1,185,600\n-\n2,853,300\n79\n15,620,220\n30,789,082\n-1,152,896\nDaewoong Pharma PHILIPPINES, INC.\n비상장\n-\n경영참여\n260,539\n-\n100\n260,539\n-\n-\n-\n-\n100\n260,539\n3,623,988\n-32,958\nDaewoong Pharmaceutical(Thailand)Co.,Ltd\xa0\n비상장\n-\n경영참여\n205,389\n-\n100\n205,389\n-\n-\n-\n-\n100\n205,389\n1,235,161\n-862,256\nPT. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA\xa0\n비상장\n-\n경영참여\n7,812,111\n-\n100\n7,812,111\n6,993,141\n6,993,141\n-\n6,993,141\n100\n14,805,252\n11,896,827\n2,929,645\nDAEWOONG PHARMACEUTICAL HONGKONG\xa0\n비상장\n-\n경영참여\n17,660,725\n269,255,424\n90\n37,184,429\n-\n-\n-\n269,255,424\n90\n37,184,429\n45,459,180\n-14,217\n북경대웅위업의약과기유한공사\n비상장\n-\n경영참여\n9,152,033\n-\n100\n5,827,684\n-\n-\n-\n-\n100\n5,827,684\n3,242,301\n150,699\n바이오시네틱스\n비상장\n-\n공동연구추진\n2,000,000\n645,000\n18\n819,086\n-\n-\n-\n645,000\n18\n819,086\n784,809\n-1,548,955\n이피피미디어\xa0\n비상장\n-\n사업목적\n1,000,000\n100,000\n20\n-\n-\n-\n-\n100,000\n20\n-\n6,294,900\n37,761\n엠디웰아이엔씨\n비상장\n-\n경영참여\n500,000\n100,000\n50\n500,000\n-\n-\n-\n100,000\n50\n500,000\n11,528,974\n1,374,650\nDaewoong America, Inc.\n비상장\n2009.12.30\n경영참여\n825,005\n-\n100\n83,286\n-\n-\n-\n-\n100\n83,286\n53,605\n-48,389\nDaewoong Pharmaceutical India Pvt.,Ltd\xa0\n비상장\n-\n경영참여\n550,733\n-\n100\n550,733\n-\n-\n-\n-\n100\n550,733\n960,934\n197,187\nDAEWOONG PHARMACEUTICAL JAPAN CO.,LTD\n비상장\n2017.03.08\n경영참여\n555,621\n1,100\n100\n555,621\n-\n-\n-\n1,100\n100\n555,621\n1,747,491\n-111,067\n건강한삶기술창업벤처PEF\xa0\n-\n2018.03.19\n사업목적\n2,500,000\n2,500,000,000\n50\n2,500,000\n-\n-\n-\n2,500,000,000\n50\n2,500,000\n4,570,795\n-87,651\n㈜다나아데이터\n비상장\n2018.11.23\n경영참여\n5,100,000\n102,000\n51\n5,100,000\n-\n-\n-\n102,000\n51\n5,100,000\n10,205,426\n76,357\nImmplacate, Inc.\n비상장\n2019.03.08\n공동연구추진\n1,125,970\n1,428,571\n20\n1,125,970\n-\n-\n-897,114\n1,428,571\n20\n228,856\n378,412\n-6,114\n아피셀테라퓨틱스\n비상장\n2020.01.23\n경영참여\n1,960,780\n1,960,780\n54\n1,960,780\n1,577,528\n7,020,000\n-\n3,538,308\n82\n8,980,780\n13,718,205\n-3,546,650\n아이엔테라퓨틱스\n비상장\n2020.05.27\n경영참여\n3,118,330\n17,414,405\n100\n3,118,330\n-\n-\n-\n17,414,405\n100\n3,118,330\n9,715,180\n-3,089,683\nDaewoong Innovation Holdings\n비상장\n2021.07.14\n경영참여\n-\n-\n-\n-\n-\n2,355,900\n-\n-\n100\n2,355,900\n2,366,987\n-3,874\nEvolus.INC(해외상장)(주3)\n-\n2021.03.23\n사업목적\n-\n-\n-\n-\n3,136,869\n57,099,225\n-32,852,922\n3,136,869\n6\n24,246,303\n257,483\n-46,810\n진켐 (주4)\n비상장\n-\n공동연구추진\n559,660\n41,932\n3\n475,551\n-\n-\n-297,927\n41,932\n0\n177,624\n12,165,407\n-5,234,563\n바이오넷(주4)\n비상장\n2001.12.22\n사업목적\n1,207,646\n324,480\n3\n227,136\n-\n-\n-\n324,480\n2\n227,136\n15,420,980\n124,314\n큐어바이오(주4)\n비상장\n-\n공동연구추진\n217,377\n31,110\n2\n308,101\n-\n-\n-283,527\n31,110\n1\n24,574\n11,886,803\n-2,895,288\n3D Matrix (해외상장)(주2)\n-\n-\n사업목적\n1,362,230\n320,000\n2\n974,980\n-\n-\n752,527\n320,000\n1\n1,727,507\n1,659,828\n-2,698,545\n카이페리온\n-\n2019.10.16\n사업목적\n1,000,020\n28,572\n3\n1,000,020\n-\n-\n-\n28,572\n3\n1,000,020\n12,399,120\n-2,919,022\nJTBC\n비상장\n-\n사업목적\n3,000,000\n600,000\n1\n166,800\n-\n-\n252,600\n600,000\n1\n419,400\n368,300,727\n-23,591,277\n향남제약공단\n비상장\n-\n일반참여\n217,879\n-\n-\n217,879\n-\n-\n-\n-\n0\n217,879\n0\n0\n자일자동차판매\n비상장\n-\n일반참여\n827,695\n-\n0\n200,098\n-\n-\n-76,495\n-\n0\n123,603\n349,756,816\n4,819,857\n대우산업개발\n비상장\n-\n일반참여\n592,014\n33,296\n0\n26,803\n-\n-\n105,715\n33,296\n0\n132,518\n307,899,612\n9,131,369\n인벤티지랩\n비상장\n2020.04.28\n기술성투자\n999,995\n83,326\n1\n999,995\n-\n-\n-\n83,326\n1\n999,995\n31,724,287\n-9,271,261\n입셀\n비상장\n2020.09.09\n기술성투자\n2,000,002\n9,091\n9\n2,000,002\n-\n-\n-\n9,091\n9\n2,000,002\n12,884,629\n-1,717,624\n데일리 임파워링 바이오 헬스케어 펀드4호\n-\n2020.09.23\n사업목적\n1,000,000\n1,000\n7\n1,000,000\n-\n-\n426,448\n1,000\n7\n1,426,448\n20,606,689\n3,239,775\n유안타 퀀텀점프 3호 투자조합\n-\n2021.09.10\n사업목적\n-\n-\n-\n-\n1,000\n1,000,000\n-\n1,000\n14\n1,000,000\n6,968,377\n-31,623\n티온랩테라퓨틱스\n비상장\n2021.07.21\n사업목적\n-\n-\n-\n-\n97,109\n738,999\n-\n97,109\n3\n738,999\n0\n0\n서울의료정보연구소\n-\n2020.12.11\n사업목적\n200,063\n1,067\n6\n200,063\n-\n-\n-\n1,067\n6\n200,063\n351,487\n-371,131\nNurron\n-\n2021.09.10\n공동연구추진\n-\n-\n-\n-\n58,343\n570,549\n-\n58,343\n2\n570,549\n2,926\n-1,481\nNeurogastrx(주3)\n-\n2021.06.18\n사업목적\n-\n-\n-\n-\n4,782,095\n3,719,705\n248,717\n4,782,095\n5\n3,968,422\n0\n0\n온코크로스\n비상장\n2021.04.01\n공동연구추진\n-\n-\n-\n-\n13,214\n1,000,036\n-\n13,214\n1\n1,000,036\n15,101,972\n-13,146,167\n넥스아이\n비상장\n2021.12.08\n공동연구추진\n-\n-\n-\n-\n11,705\n999,958\n-\n11,705\n4\n999,958\n0\n0\n씨어스\n비상장\n2021.12.22\n사업목적\n-\n-\n-\n-\n8,284\n5,000,057\n-\n8,284\n3\n5,000,057\n23,588,842\n-4,430,563\n미래에셋-현대중공업 신성장투자조합1호\n-\n2021.11.01\n사업목적\n-\n-\n-\n-\n400\n400,000\n-\n400\n6\n400,000\n6,590,146\n-111,064\n에버그린투자파트너스4호펀드\n-\n2021.11.17\n사업목적\n-\n-\n-\n-\n200\n200,000\n-\n200\n2\n200,000\n8,541,946\n-78,274\n브이원바이오\n비상장\n2021.11.30\n사업목적\n-\n-\n-\n-\n21,667\n390,006\n-\n21,667\n9\n390,006\n0\n0\n엑소스템텍\n비상장\n2021.12.30\n공동연구추진\n-\n-\n-\n-\n38,865\n999,996\n-\n38,865\n1\n999,996\n11,272,228\n-7,330,580\n합 계\n-\n-\n205,947,372\n16,840,420\n89,673,172\n-32,621,978\n2,828,190,619\n-\n262,998,566\n1,572,513,771\xa0\n-53,337,888\n(주1) 상기 최근사업연도 재무현황은 21년 기말 재무제표 기준입니다.(주2) 3D Matrix는 4월 결산법인으로 2021년 4월말 기준 재무제표이며 재무현황 표기 단위는 천엔입니다.(주3) Evolus, Nurrron, Neurogastrx 재무현황 표기 단위는 천달러입니다.(주4) 20년 기말 재무현황입니다. \xa0* 출자목적 세부내용\xa0\r\n법인명\n출자목적\n세부 목적\n큐어바이오\n공동연구 추진\n폐암치료제 공동 R&D\nNurron\n공동연구 추진\n파킨슨 치료제 개발 업체 투자\n넥스아이\n공동연구 추진\n파이프라인 공동연구 개발\nImmplacate, Inc.\n공동연구 추진\n줄기세포치료제 공동연구/개발\n바이오시네틱스\n공동연구 추진\n나노기술 활용 신약개발\n온코크로스\n공동연구 추진\n공동연구 및 양사 협력관계 강화\n엑소스템텍\n공동연구 추진\nDW-MSC 엑소좀 파이프라인 확장/MOU 체결\n진켐\n공동연구 추진\nAnti-Sense 항암제 등 공동 R&D\n인벤티지랩\n기술성 투자\n장기지속형 주사제 파이프라인 발굴\n입셀\n기술성 투자\n유망 파이프라인 선확보\n브이원바이오\n사업목적\n마이크로바이옴 연구협력\n티온랩테라퓨틱스\n사업목적\n서방형 데포치료제 연구협력\nNeurogastrx\n사업목적\n펙수프라잔 미국 L/O 대금 일부에 대한 지분 취득\n씨어스\n사업목적\n패치형 심전도기/병상모니터링 관련 사업협업\nEvolus.INC(해외상장)\n사업목적\n파트너 재무구조 개선 및 파트너십 강화\nJTBC\n사업목적\n우호적인 종편채널 확보\n카이페리온\n사업목적\n신사업 O/C 강화\n서울의료정보연구소\n사업목적\n보건의료데이터 사업분야 전략적 협업\n바이오넷\n사업목적\n내시경 등 의료기기 사업 투자\n자일자동차판매\n일반참여\n투자수익 창출\n대우산업개발\n일반참여\n투자수익 창출\n3D Matrix (해외상장)\n사업목적\n흡수성 국소지혈제 국내 판권 확보\n에버그린투자파트너스4호펀드\n사업목적\n연구개발 스타트업 발굴\n미래에셋-현대중공업 신성장투자조합1호\n사업목적\n중장기 미래 파이프라인 동력 및 네트워크 확보\n데일리 임파워링 바이오 헬스케어 펀드4호\n사업목적\n바이오 기업 발굴 등 신사업 O/C 강화\n유안타 퀀텀점프 3호 투자조합\n사업목적\n목적펀드 내 투자회사와의 글로벌 사업 진출 협력\n건강한삶기술창업벤처PEF\xa0\n사업목적\n펀드참여\n* 장부가액 감액 사유\n(단위 : 천원)\n법인명\n감액금액\n감액 사유\nEvolus.INC\n-32,852,922.00\n시가평가에 따른 공정가치 감소\n자일자동차판매\xa0\n-76,495\n진켐\xa0\n-297,927\n큐어바이오\n-283,527\nImmplacate, Inc.\n-897,114\n회수가능액을 고려한 장부금액 감소\n']"
